Page 1143 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 63 Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children 1004.e5

183. Passmore SJ, Chessells JM, Kempski H, et al: Paediatric myelodys- 204. Patja K, Pukkala E, Sund R, et al: Cancer incidence of persons with
plastic syndromes and juvenile myelomonocytic leukaemia in the UK: Down syndrome in Finland: a population-based study. Int J Cancer
a population-based study of incidence and survival. Br J Haematol 118:1769, 2006.
121:758, 2003. 205. Lange B: The management of neoplastic disorders of haematopoiesis in
184. Bresolin S, Zecca M, Flotho C, et al: Gene expression-based classi- children with Down’s syndrome. Br J Haematol 110:512, 2000.
fication as an independent predictor of clinical outcome in juvenile 206. Zipursky A: Transient leukaemia—a benign form of leukaemia in
myelomonocytic leukemia. J Clin Oncol 28:1919, 2010. newborn infants with trisomy 21. Br J Haematol 120:930, 2003.
185. Yoshida N, Yagasaki H, Xu Y, et al: Correlation of clinical features with 207. Gamis AS, Alonzo TA, Gerbing RB, et al: Natural history of transient
the mutational status of GM-CSF signaling pathway-related genes in myeloproliferative disorder clinically diagnosed in Down syndrome
juvenile myelomonocytic leukemia. Pediatr Res 65:334, 2009. neonates: a report from the Children’s Oncology Group Study A2971.
186. Niemeyer CM, Arico M, Basso G, et al: Chronic myelogenous leukemia Blood 118:6752, 2011.
in childhood: a retrospective analysis of 110 cases. European Working 208. Bhatnagar N, Nizery L, Tunstall O, et al: Transient abnormal myelo-
Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). poiesis and AML in Down syndrome: an update. Curr Hematol Malig
Blood 89:3534, 1997. Rep 11:333, 2016.
187. Chan HS, Estrov Z, Weitzman SS, et al: The value of intensive com- 209. Yoshida K, Toki T, Okuno Y, et al: The landscape of somatic mutations
bination chemotherapy for juvenile chronic myelogenous leukemia. in Down syndrome-related myeloid disorders. Nat Genet 45:1293,
J Clin Oncol 5:1960, 1987. 2013.
188. Chan GC, Wang WC, Raimondi SC, et al: Myelodysplastic syndrome 210. Liu B, Filippi S, Roy A, et al: Stem and progenitor cell dysfunction in
in children: differentiation from acute myeloid leukemia with a low human trisomies. EMBO Rep 16:44, 2015.
blast count. Leukemia 11:206, 1997. 211. Tunstall-Pedoe O, Roy A, Karadimitris A, et al: Abnormalities in the
189. Hasle H, Kerndrup G, Yssing M, et al: Intensive chemotherapy in myeloid progenitor compartment in Down syndrome fetal liver precede
childhood myelodysplastic syndrome. A comparison with results in acquisition of GATA1 mutations. Blood 112:4507, 2008.
acute myeloid leukemia. Leukemia 10:1269, 1996. 212. Roy A, Cowen G, Mead AJ, et al: Perturbation of fetal liver hemato-
190. Estrov Z, Dube ID, Chan HS, et al: Residual juvenile chronic poietic stem and progenitor cell development by trisomy 21. Proc Natl
myelogenous leukemia cells detected in peripheral blood during clinical Acad Sci USA 109:17579, 2012.
remission. Blood 70:1466, 1987. 213. Wechsler J, Greene M, McDevitt MA, et al: Acquired mutations in
191. Festa RS, Shende A, Lanzkowsky P: Juvenile chronic myelocytic leuke- GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat
mia: experience with intensive combination chemotherapy. Med Pediatr Genet 32:148, 2002.
Oncol 18:311, 1990. 214. Groet J, McElwaine S, Spinelli M, et al: Acquired mutations in GATA1
192. Lilleyman JS, Harrison JF, Black JA: Treatment of juvenile chronic in neonates with Down’s syndrome with transient myeloid disorder.
myeloid leukemia with sequential subcutaneous cytarabine and oral Lancet 361:1617, 2003.
mercaptopurine. Blood 49:559, 1977. 215. Hitzler JK, Cheung J, Li Y, et al: GATA1 mutations in transient
193. Wasserman LR: The management of polycythaemia vera. Br J Haematol leukemia and acute megakaryoblastic leukemia of Down syndrome.
21:371, 1971. Blood 101:4301, 2003.
194. Maybee D, Dubowy R: Toxicity of high-dose alpha inferferon in 216. Mundschau G, Gurbuxani S, Gamis AS, et al: Mutagenesis of GATA1
children with Philadelphia chromosome-positive chronic myelogenous is an initiating event in Down syndrome leukemogenesis. Blood
leukemia: a Pediatric Oncology Group study. Proc Natl Acad Sci USA 101:4298, 2003.
12:323, 1993. 217. Xu G, Nagano M, Kanezaki R, et al: Frequent mutations in the
195. Stieglitz E, Ward AF, Gerbing RB, et al: Phase II/III trial of a pre- GATA-1 gene in the transient myeloproliferative disorder of Down
transplant farnesyl transferase inhibitor in juvenile myelomonocytic syndrome. Blood 102:2960, 2003.
leukemia: a report from the Children’s Oncology Group. Pediatr Blood 218. Calligaris R, Bottardi S, Cogoi S, et al: Alternative translation initiation
Cancer 62:629, 2015. site usage results in two functionally distinct forms of the GATA-1
196. Archambeault S, Flores NJ, Yoshimi A, et al: Development of an transcription factor. Proc Natl Acad Sci USA 92:11598, 1995.
allele-specific minimal residual disease assay for patients with juvenile 219. Kuhl C, Atzberger A, Iborra F, et al: GATA1-mediated megakaryocyte
myelomonocytic leukemia. Blood 111:1124, 2008. differentiation and growth control can be uncoupled and mapped to
197. Locatelli F, Nollke P, Zecca M, et al: Hematopoietic stem cell trans- different domains in GATA1. Mol Cell Biol 25:8592, 2005.
plantation (HSCT) in children with juvenile myelomonocytic leukemia 220. Li Z, Godinho FJ, Klusmann JH, et al: Developmental stage-selective
(JMML): results of the EWOG-MDS/EBMT trial. Blood 105:410, effect of somatically mutated leukemogenic transcription factor GATA1.
2005. Nat Genet 37:613, 2005.
198. Manabe A, Okamura J, Yumura-Yagi K, et al: Allogeneic hematopoietic 221. Muntean AG, Crispino JD: Differential requirements for the activation
stem cell transplantation for 27 children with juvenile myelomonocytic domain and FOG-interaction surface of GATA-1 in megakaryocyte
leukemia diagnosed based on the criteria of the International JMML gene expression and development. Blood 106:1223, 2005.
Working Group. Leukemia 16:645, 2002. 222. Mateow MK, Barbaric D, Byatt S-A, et al: Down syndrome and leu-
199. Yoshimi A, Niemeyer CM, Bohmer V, et al: Chimaerism analyses and kemia: insights into leukemiogenesis and translationsl targets. Transl
subsequent immunological intervention after stem cell transplantation Pediatr 4:76, 2015.
in patients with juvenile myelomonocytic leukaemia. Br J Haematol 223. Walters DK, Mercher T, Gu TL, et al: Activating alleles of JAK3 in
129:542, 2005. acute megakaryoblastic leukemia. Cancer Cell 10:65, 2006.
200. Inagaki J, Fukano R, Nishikawa T, et al: Outcomes of immunologi- 224. Kiyoi H, Yamaji S, Kojima S, et al: JAK3 mutations occur in acute
cal interventions for mixed chimerism following allogeneic stem cell megakaryoblastic leukemia both in Down syndrome children and non-
transplantation in children with juvenile myelomonocytic leukemia. Down syndrome adults. Leukemia 21:574, 2007.
Pediatr Blood Cancer 60:116, 2013. 225. De Vita S, Mulligan C, McElwaine S, et al: Loss-of-function JAK3
201. Faraci M, Micalizzi C, Lanino E, et al: Three consecutive related bone mutations in TMD and AMKL of Down syndrome. Br J Haematol
marrow transplants for juvenile myelomonocytic leukaemia. Pediatr 137:337, 2007.
Transplant 9:797, 2005. 226. Karandikar NJ, Aquino DB, McKenna RW, et al: Transient myelo-
202. Smith FO, King R, Nelson G, et al: Unrelated donor bone marrow proliferative disorder and acute myeloid leukemia in Down syn-
transplantation for children with juvenile myelomonocytic leukaemia. drome. An immunophenotypic analysis. Am J Clin Pathol 116:204,
Br J Haematol 116:716, 2002. 2001.
203. Yoshimi A, Bader P, Matthes-Martin S, et al: Donor leukocyte infusion 227. Tchernia G, Lejeune F, Boccara JF, et al: Erythroblastic and/or mega-
after hematopoietic stem cell transplantation in patients with juvenile karyoblastic leukemia in Down syndrome: treatment with low-dose
myelomonocytic leukemia. Leukemia 19:971, 2005. arabinosyl cytosine. J Pediatr Hematol Oncol 8:59, 1996.